Tag Archives: CVRs

Hitting The Milestones: Update On Earning “Biobucks”
December 8, 2016

Earnout payments have been nearly ubiquitous in biotech M&A transactions for the past decade. Given the risks, costs, and timelines in drug R&D, these contingent value rights, or “biobucks”, play an important role in bridging the gap in valuation expectations

Leave a comment